Kowa Livalo Deal With Mitsubishi Tanabe Highlights Broader Expansion Plans
This article was originally published in PharmAsia News
Executive Summary
Mitsubishi Tanabe Pharma has agreed to market Nagoya-based drug maker Kowa's cholesterol drug Livalo (pitavastatin) through subsidiaries in Taiwan and Indonesia in a deal that shows how nimble a mid-sized Japanese firm is quickly expanding outside the home market as it gears up to enter the U.S., Canada and Europe